Literature DB >> 8648678

Differences in the susceptibility of herpes simplex virus types 1 and 2 to modified heparin compounds suggest serotype differences in viral entry.

B C Herold1, S I Gerber, B J Belval, A M Siston, N Shulman.   

Abstract

Although heparan sulfate (HS) serves as an initial receptor for the binding of both herpes simplex virus type 1 (HSV-1) and HSV-2 to cell surfaces, the two serotypes differ in epidemiology, cell tropism, and ability to compete for viral receptors in vitro. These observations are not necessarily contradictory and can be explained if the two serotypes recognize different structural features of HS. To compare the specific features of HS important for the binding and infection of HSV-1 and HSV-2, we took advantage of structural similarities between heparin and cell surface HS and compared the abilities of chemically modified heparin compounds to inhibit plaque formation. We found that the antiviral activity of heparin for both serotypes was independent of anticoagulant activity. Moreover, specific negatively charged regions of the polysaccharide, including N sulfations and the carboxyl groups, are key structural features for interactions of both HSV-1 and HSV-2 with cell surfaces since N desulfation or carboxyl reduction abolished heparin's antiviral activity. In contrast, 6-O sulfations and 2-,3-O sulfations are important determinants primarily for HSV- 1 infection. The O-desulfated heparins had little or no inhibitory effect on HSV-1 infection but inhibited HSV-2 infection. Using a series of intertypic recombinant mutant viruses, we found that susceptibility to O-desulfated heparins can be transferred to HSV-1 by the gene for glycoprotein C of HSV-2 (gC-2). This supports the notion that the envelope glycoproteins of HSV-1 and HSV-2 interact with different affinities for different structural features of heparin. To determine if the modified heparin compounds inhibited plaque formation by competing with cell surface HS for viral attachment, binding studies were also performed. As anticipated, most compounds inhibited binding and plaque formation in parallel. However, several compounds inhibited the binding of HSV-1 to cells during the initial attachment period at 4 degrees C; this inhibitory effect was reversed when the cells and inoculum were shifted to 37 degrees C. This temperature-dependent differential response to modified heparin compounds was evident primarily when glycoprotein C of HSV-1 (gC-1) was present in the virion envelope. Minimal temperature-dependent differences were seen for HSV-1 with gC-1 deleted and for HSV-2. These results suggest differences in the interactions of HSV-1 and HSV-2 with cell surface HS that may influence cell tropism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8648678      PMCID: PMC190219     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate.

Authors:  J E Turnbull; D G Fernig; Y Ke; M C Wilkinson; J T Gallagher
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

2.  Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration.

Authors:  A O Fuller; W C Lee
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Resistance of herpes simplex virus type 2 to neomycin maps to the N-terminal portion of glycoprotein C.

Authors:  A M Oyan; K E Dolter; N Langeland; W F Goins; J C Glorioso; L Haarr; C S Crumpacker
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  Herpes simplex virus infection and propagation in a mouse L cell mutant lacking heparan sulfate proteoglycans.

Authors:  S Gruenheid; L Gatzke; H Meadows; F Tufaro
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

5.  Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate.

Authors:  T Compton; D M Nowlin; N R Cooper
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

6.  Structure, composition and heparin binding properties of a human cytomegalovirus glycoprotein complex designated gC-II.

Authors:  B Kari; R Gehrz
Journal:  J Gen Virol       Date:  1993-02       Impact factor: 3.891

7.  Glycoproteins gIII and gp50 play dominant roles in the biphasic attachment of pseudorabies virus.

Authors:  A Karger; T C Mettenleiter
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

Review 8.  Integral membrane heparan sulfate proteoglycans.

Authors:  G David
Journal:  FASEB J       Date:  1993-08       Impact factor: 5.191

9.  Structure of a heparan sulphate oligosaccharide that binds to basic fibroblast growth factor.

Authors:  H Habuchi; S Suzuki; T Saito; T Tamura; T Harada; K Yoshida; K Kimata
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

10.  Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans.

Authors:  M T Shieh; D WuDunn; R I Montgomery; J D Esko; P G Spear
Journal:  J Cell Biol       Date:  1992-03       Impact factor: 10.539

View more
  39 in total

Review 1.  Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry.

Authors:  D Shukla; P G Spear
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

2.  Characterization of a BHK(TK-) cell clone resistant to postattachment entry by herpes simplex virus types 1 and 2.

Authors:  R J Roller; B C Herold
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Heparan sulfate-independent infection attenuates high-neurovirulence GDVII virus-induced encephalitis.

Authors:  Honey V Reddi; A S Manoj Kumar; Aisha Y Kung; Patricia D Kallio; Brian P Schlitt; Howard L Lipton
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 4.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

5.  Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.

Authors:  Hermann Bultmann; Jeremy Teuton; Curtis R Brandt
Journal:  Antimicrob Agents Chemother       Date:  2007-01-29       Impact factor: 5.191

6.  Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity.

Authors:  N Kaludov; K E Brown; R W Walters; J Zabner; J A Chiorini
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

7.  Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry.

Authors:  Christopher D O'Donnell; Maria Kovacs; Jihan Akhtar; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Virology       Date:  2009-12-11       Impact factor: 3.616

8.  Using a 3-O-sulfated heparin octasaccharide to inhibit the entry of herpes simplex virus type 1.

Authors:  Ronald Copeland; Arun Balasubramaniam; Vaibhav Tiwari; Fuming Zhang; Arlene Bridges; Robert J Linhardt; Deepak Shukla; Jian Liu
Journal:  Biochemistry       Date:  2008-05-06       Impact factor: 3.162

9.  Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread.

Authors:  S Laquerre; R Argnani; D B Anderson; S Zucchini; R Manservigi; J C Glorioso
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.